SHANGHAI – Eddingpharm Co. Ltd. will develop and commercialize Cardiome Pharma Corp.'s atrial fibrillation drug, Brinavess (vernakalant), paying $1 million up front for the Greater China rights with potential for the Vancouver, British Columbia-based Cardiome to receive $3 million more in regulatory milestone payments.